Section to complete information about the primary medical condition(s) or problem(s) studied and, a characteristics of the intervention(s).
Health condition(s) or Problem(s) studied:
Hormone refractory prostate cancer
Health condition(s) code:
Prostatic Neoplasms
Genital Neoplasms, Male
Urogenital Neoplasms
Genital Diseases, Male
Urogenital Diseases, Male
Prostatic Diseases
Intervention(s):
Group I (Experimental): HER-1 dose 100 µg by intramuscular route. Patients will receive 9 immunizations in days 0, 14, 28, 42, 56, 84, 112, 140 y 168.
Group II (Experimental): HER-1 dose 200 µg by intramuscular route. Patients will receive 9 immunizations in days 0, 14, 28, 42, 56, 84, 112, 140 y 168.
Group III (Experimental): HER-1 dose 400 µg by intramuscular route. Patients will receive 9 immunizations in days 0, 14, 28, 42, 56, 84, 112, 140 y 168.
Group IV (Experimental): HER-1 dose 600 µg by intramuscular route. Patients will receive 9 immunizations in days 0, 14, 28, 42, 56, 84, 112, 140 y 168.
Group V (Experimental): HER-1 dose 800 µg by intramuscular route. Patients will receive 9 immunizations in days 0, 14, 28, 42, 56, 84, 112, 140 y 168
Intervention code:
Receptor, Epidermal Growth Factor
Vaccines
Immunization
Injections, Intramuscular